Ken Griffin Poly Pid Ltd. Call Options Transaction History

Citadel Advisors LLC

  • $505 Billion
  • Q3 2024

Call Options

2 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q4 2022

Feb 14, 2023
SELL
$0.66 - $38.7 $4,686 - $274,770
-7,100 Reduced 47.97%
7,700 $5,000
Q3 2022

Nov 14, 2022
SELL
$1.06 - $36.9 $62,434 - $2.17 Million
-58,900 Reduced 79.92%
14,800 $17,000

About PolyPid Ltd.

PYPD Quotes by TradingView
  • Ticker PYPD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 19,551,200
  • Market Cap $69.6M
  • Description
  • PolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in Phase III clinical trial for the prevention of sternal (bone) surgical site infections (SSIs), as well a...
More about PYPD
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email